We are live on ! Find out more
PCVX icon

Vaxcyte
PCVX

223 hedge funds and large institutions have $6.51B invested in Vaxcyte in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 86 increasing their positions, 69 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

236% more call options, than puts

Call options by funds: $9.9M | Put options by funds: $2.94M

131% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 16

26% more capital invested

Capital invested by funds: $5.17B → $6.51B (+$1.34B)

25% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 69

10% more funds holding

Funds holding: 202 → 223 (+21)

8% more funds holding in top 10

Funds holding in top 10: 13 → 14 (+1)

0.88% more ownership

Funds ownership: 108.03% → 108.91% (+0.88%)

Holders
223
Holders Change
+21
Holders Change %
+10.4%
% of All Funds
3.25%
Holding in Top 10
14
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+7.69%
% of All Funds
0.2%
New
37
Increased
86
Reduced
69
Closed
16
Calls
$9.9M
Puts
$2.94M
Net Calls
+$6.96M
Net Calls Change
+$6.35M

Top Buyers

1
BlackRock
BlackRock
New York
+$60M
2
Morgan Stanley
Morgan Stanley
New York
+$34.5M
3
DGM
Darwin Global Management
Jersey
+$30.1M
4
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$23.5M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$20M

Top Sellers

1
MVM
Medicxi Ventures Management
Jersey
-$53.5M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$32.3M
3
FAM
Fred Alger Management
New York
-$22M
4
NIP
Nicholas Investment Partners
California
-$18.1M
5
B
Braidwell
Connecticut
-$17.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
MLICM
176
Metropolitan Life Insurance Company (MetLife)
New York
$334K -$6.08K -117 -2%
AWM
177
Avior Wealth Management
Nebraska
$293K +$61.4K +1,183 +34%
KeyBank National Association
178
KeyBank National Association
Ohio
$272K -$11.9K -229 -5%
RG
179
Rathbones Group
United Kingdom
$272K – – –
Mackenzie Financial
180
Mackenzie Financial
Ontario, Canada
$248K -$94.2K -1,813 -31%
Daiwa Securities Group
181
Daiwa Securities Group
Japan
$244K +$185K +3,568 +1,122%
Pathstone Holdings
182
Pathstone Holdings
New Jersey
$236K +$195K +3,757 New
Osaic Holdings
183
Osaic Holdings
Arizona
$236K +$14.5K +279 +8%
FCM
184
Farallon Capital Management
California
$214K +$177K +3,400 New
VPIM
185
Vanguard Personalized Indexing Management
California
$208K +$172K +3,307 New
SRL
186
Scientech Research LLC
New Jersey
$204K +$169K +3,255 New
BC
187
Bridgefront Capital
Texas
$202K +$167K +3,209 New
OAM
188
Oppenheimer Asset Management
New York
$201K +$166K +3,198 New
VIA
189
Virtus Investment Advisers
Connecticut
$200K – – –
KBC Group
190
KBC Group
Belgium
$97K – – –
VEA
191
Virtus ETF Advisers
New York
$96K -$18.4K -355 -19%
Nisa Investment Advisors
192
Nisa Investment Advisors
Missouri
$74.7K -$61.9K -1,192 -50%
EC
193
EntryPoint Capital
New York
$58.5K +$48.4K +932 New
FHA
194
First Horizon Advisors
Tennessee
$50.7K – – –
BCV
195
Banque Cantonale Vaudoise
Switzerland
$38K +$31.3K +602 New
CA
196
Clearstead Advisors
Ohio
$33.9K -$14.5K -280 -34%
LC
197
Lindbrook Capital
California
$25.8K -$208 -4 -1%
PA
198
Parallel Advisors
California
$25.8K +$13K +250 +155%
S
199
SignatureFD
Georgia
$25.7K +$3.12K +60 +17%
CSC
200
Caldwell Sutter Capital
California
$22.5K – – –
6 7
8
9 10

PCVX Hedge Fund Activity: Q4 2023 in Review

223 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q4 2023, worth a combined $6.51B — up 26% from $5.17B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new PCVX positions and 16 closed out — a net gain of 21 holders — while 86 added to existing stakes and 69 trimmed.

The largest buyer was BlackRock, adding an estimated $60M. The largest seller was Medicxi Ventures Management, exiting entirely with an estimated $53.5M sold.

  • 223 institutional investors held Vaxcyte (PCVX) as of Q4 2023, up from 202 in Q3 2023.
  • Funds reported $6.51B of Vaxcyte stock for Q4 2023, up 26% quarter-over-quarter.
  • 37 funds opened new Vaxcyte positions in Q4 2023 and 16 closed out, a net change of +21 holders.
  • The largest Vaxcyte buyer in Q4 2023 was BlackRock, an estimated $60M added.
  • The largest Vaxcyte seller in Q4 2023 was Medicxi Ventures Management, an estimated $53.5M sold.

Based on aggregated 13F filings for Q4 2023.